Gemcitabine (G) /carboplatin (C) surveillance study in patients with advanced or metastatic non-small cell lung cancer (NSCLC): Survival update of a phase II study of a 21 versus 28-day schedule.

Abstract

7134 Background: The combination of G and C is active and widely used for advanced NSCLC. For Gemzar administered on days 1,8 and 15 dose-limiting toxicity was thrombocytopenia. This study compared two different combinations of C with G (days 1,8) to identify a schedule with superior therapeutic index. METHODS 499 chemonaive patients with stage IIIB-IV… (More)

Topics

Cite this paper

@article{Obasaju2004Gemcitabine, title={Gemcitabine (G) /carboplatin (C) surveillance study in patients with advanced or metastatic non-small cell lung cancer (NSCLC): Survival update of a phase II study of a 21 versus 28-day schedule.}, author={Coleman K. Obasaju and Z. Ye and Jose Eduardo Loureiro Jorge and Adrian R W Hatfield}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2004}, volume={22 14_suppl}, pages={7134} }